| Similar Articles |
|---|
 |
The Motley Fool
October 7, 2004
Charly Travers |
Santarus Takes on Big Pharma Can this small drug company compete with the industry's giants? Santarus bolstered its marketing efforts with the signing of a very beneficial partnership with Otsuka America Pharmaceutical.   |
The Motley Fool
April 27, 2004
Charly Travers |
More Biotech IPOs Can small biotech take on big pharma? You bet. A new biotech company decides to use its technology to battle large pharma head on. If all goes well, this could be one of the biggest drug development stories of the year. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
December 3, 2009
Brian Orelli |
I Love This Industry With double-digit gains, how could you not love the biotech industry? |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
November 8, 2006
Brian Lawler |
Will Santarus Heal Investors' Heartburn? This pharma's fortunes will rise or fall on its single drug. In a few quarters, investors should be able see if this is worth their consideration. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
June 22, 2010
Dave Mock |
A Big Upgrade for DepoMed This bullish call comes from more than just one analyst. |
The Motley Fool
January 28, 2005
Karl Thiel |
Will the FDA Kill Biotech? Proposed legislation could spell changes across the pharmaceutical world. Investors are right to be nervous. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
American Family Physician
October 1, 2003
Heidelbaugh et al. |
Management of Gastroesophageal Reflux Disease This article summarizes an evidence-based approach to the cost-effective management of patients with GERD. |
